Maxim Group Upgrades Theriva Biologics (NYSEAMERICAN:TOVX) to Buy

Theriva Biologics (NYSEAMERICAN:TOVX) was upgraded by equities research analysts at Maxim Group from a “hold” rating to a “buy” rating in a note issued to investors on Tuesday, Marketbeat Ratings reports. The brokerage currently has a $1.00 price objective on the stock. Maxim Group’s price target points to a potential upside of 341.31% from the company’s current price.

Theriva Biologics Price Performance

TOVX opened at $0.23 on Tuesday. The company has a fifty day moving average price of $0.19 and a two-hundred day moving average price of $0.26. The company has a debt-to-equity ratio of 0.11, a quick ratio of 1.74 and a current ratio of 1.74. Theriva Biologics has a 52 week low of $0.16 and a 52 week high of $1.50. The firm has a market capitalization of $7.65 million, a PE ratio of -0.01 and a beta of 0.47.

Theriva Biologics (NYSEAMERICAN:TOVX) last posted its quarterly earnings results on Thursday, March 12th. The company reported $1.30 earnings per share for the quarter.

Institutional Trading of Theriva Biologics

An institutional investor recently raised its position in Theriva Biologics stock. Geode Capital Management LLC boosted its holdings in shares of Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) by 651.8% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 212,087 shares of the company’s stock after acquiring an additional 183,878 shares during the period. Geode Capital Management LLC owned approximately 0.63% of Theriva Biologics worth $45,000 as of its most recent filing with the Securities and Exchange Commission. 6.17% of the stock is currently owned by hedge funds and other institutional investors.

About Theriva Biologics

Theriva Biologics, Inc, a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. The company’s lead product candidate is VCN-01, a clinical stage oncolytic human adenovirus that is in a Phase 2 clinical study for the treatment of pancreatic cancer; a Phase 1 clinical study for the treatment of retinalblastoma; a Phase 1 clinical study for the treatment of head and neck squamous cell carcinoma; and a Phase 1 clinical study for the treatment of solid tumors.